Solid Biosciences to Present at the Jefferies London Healthcare Conference
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's President and CEO, Bo Combo, along with Chief Medical Officer Gabriel Brooks, M.D., will deliver a presentation on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
The presentation will be accessible via live webcast on the company's website's Investors section under Events, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.
Solid Biosciences (Nasdaq: SLDB), un'azienda di medicine genetiche di precisione, ha annunciato la sua partecipazione al prossimo Jefferies London Healthcare Conference. Il Presidente e CEO dell'azienda, Bo Combo, insieme al Chief Medical Officer Gabriel Brooks, M.D., presenterà un intervento mercoledì 20 novembre 2024, alle 13:30 GMT (8:30 a.m. ET).
La presentazione sarà accessibile tramite webcast dal vivo nella sezione Investitori del sito web dell'azienda, sotto Eventi, con una registrazione disponibile per 30 giorni successivi. Gli investitori istituzionali possono organizzare incontri con la direzione tramite i loro rappresentanti Jefferies.
Solid Biosciences (Nasdaq: SLDB), una empresa de medicamentos genéticos de precisión, ha anunciado su participación en la próxima Jefferies London Healthcare Conference. El Presidente y CEO de la empresa, Bo Combo, junto con el Director Médico Gabriel Brooks, M.D., realizará una presentación el miércoles 20 de noviembre de 2024, a la 1:30 p.m. GMT (8:30 a.m. ET).
La presentación será accesible a través de una transmisión en vivo en la sección de Inversores del sitio web de la empresa, en Eventos, con una grabación disponible durante 30 días después. Los inversores institucionales pueden organizar reuniones con la dirección a través de sus representantes de Jefferies.
솔리드 바이오사이언스 (Nasdaq: SLDB), 정밀 유전자 의약품 회사가 다가오는 제퍼리스 런던 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 회장 겸 CEO인 Bo Combo와 수석 의학 책임자 Gabriel Brooks, M.D.가 2024년 11월 20일 수요일 오후 1시 30분 GMT (동부 표준시 8시 30분)에 발표를 진행할 예정입니다.
이 발표는 회사 웹사이트의 투자자 섹션 하의 이벤트를 통해 실시간 웹캐스트로 접근할 수 있으며, 이후 30일 동안 재생 가능했습니다. 기관 투자자들은 제퍼리스 대표를 통해 경영진과의 미팅을 주선할 수 있습니다.
Solid Biosciences (Nasdaq: SLDB), une entreprise de médicaments génétiques de précision, a annoncé sa participation à la prochaine Jefferies London Healthcare Conference. Le Président et CEO de l'entreprise, Bo Combo, ainsi que le Directeur Médical Gabriel Brooks, M.D., présenteront un exposé le mercredi 20 novembre 2024, à 13h30 GMT (8h30 ET).
L'exposé sera accessible en direct via un webinaire sur la section Investisseurs du site Web de l'entreprise, sous Événements, avec une rediffusion disponible pendant 30 jours après. Les investisseurs institutionnels peuvent organiser des réunions avec la direction par l'intermédiaire de leurs représentants Jefferies.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen für präzise Gentherapien, hat seine Teilnahme an der bevorstehenden Jefferies London Healthcare Conference bekannt gegeben. Der Präsident und CEO des Unternehmens, Bo Combo, sowie der Chief Medical Officer Gabriel Brooks, M.D., werden am Mittwoch, den 20. November 2024, um 13:30 Uhr GMT (8:30 Uhr ET) eine Präsentation halten.
Die Präsentation wird über einen Live-Stream im Bereich Investoren auf der Website des Unternehmens unter Veranstaltungen zugänglich sein, mit einer Wiederholung, die 30 Tage lang verfügbar ist. Institutionelle Investoren können über ihre Jefferies-Vertreter Meetings mit dem Management vereinbaren.
- None.
- None.
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at the Jefferies London Healthcare Conference 2024?
How can investors watch Solid Biosciences' (SLDB) Jefferies Conference presentation?
Who will represent Solid Biosciences (SLDB) at the 2024 Jefferies London Healthcare Conference?
How can institutional investors meet with Solid Biosciences (SLDB) management at the Jefferies Conference?
